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Background: Two current theories regarding the neuroscientific bases of mood
disorders involve alterations in glutamatergic neurotransmission and excessive activation
of inflammatory pathways. We hypothesized that glutamate (Glu) levels and peripheral
inflammatory markers would be associated with cognitive function, in patients with
Bipolar Disorder Type II (BP-II), and that such factors would be associated with
psychological treatment outcomes.
Aims: The primary aim of this study was to explore the relationship between the
neurotransmitter Glu, cytokines (CRP, IL_6, and TNFa) and neuropsychological and
related functioning. The secondary aim was to assess cognitive functioning as a predictor
of poor response to psychological therapy.
Methods: Proton magnetic resonance spectroscopy data were acquired from the
anterior cingulate cortex (ACC) of 15 participants with BP-II, and 13 healthy controls in
a 3T magnetic resonance imaging scanner. The Digit Symbol Task (DST) for processing
speed, TMT-B for executive function and Rey Auditory Verbal Learning Test (RAVLT) were
administered to assess cognitive domains.
Results: There was no significant difference in anterior cingulate Glu, or inflammatory
markers between groups. Furthermore, we found no significant difference between
groups in any cognitive tests. Scores on the DSTwere found to be significantly associated
with poor response to psychological therapy.
Conclusions: This study may highlight an association between neuropsychological
dysfunction and treatment outcome in euthymic patients with BP-II. We did not find any
association between peripheral inflammatory markers and brain Glu levels. This may have
been in part due to the small sample size.
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INTRODUCTION
Mood disorders are highly prevalent and represent a significant
public health burden (1). Psychological treatments are thought
to be effective modes of treatment for depression and anxiety,
yet there are a substantial number of patients who do not
benefit (2). It is therefore possible that underlying biological
or neuro-psychological mechanisms are involved in preventing
patients from fully benefiting from therapy. Due to the severity
and co-morbidity of treatment resistant populations, it is
likely that patients are not receiving the right treatment to
suit their individual needs. To address this problem, more
refined approaches are needed to target specific biological and
cognitive domains. Two current areas of focus regarding the
neuroscientific basis of mood disorders involve alterations in
glutamatergic neurotransmission and excessive activation of
inflammatory pathways (3).
Since glutamate mediates cognition and behavior (4) and
the predominant role of glutamate receptors appears to be
the modulation of synaptic plasticity, a property of the brain
thought to be vital for memory and learning (5), it is plausible
that dysregulation of the glutamatergic system may be involved
in treatment resistant mood disorders. Disruption of this
system has been consistently implicated in psychiatric illnesses,
including major depressive disorder (MDD) and bipolar disorder
(BP), in multiple brain areas using proton magnetic resonance
spectroscopy (1H-MRS) (3, 6, 7). This technique allows in vivo
assessment of the chemical composition of tissues in a non-
invasive manner, by using the magnetic resonance signal of
hydrogen to determine the concentrations of variousmetabolites,
including glutamate.
Studies using single voxel 1H-MRS in the anterior cingulate
cortex (ACC), in MDD have consistently reported lower
glutamatergic metabolites glutamate (Glu), glutamine (Gln),
or Glx (Glu+Gln) (8–12). Studies in bipolar disorder have
demonstrated inconsistent results but suggest that levels may
be elevated (9, 10, 13). Such inconsistencies may be due to
the difference in mood phase between various studies. For
example, patients with mania show elevated Glx levels in the left
dorsolateral prefrontal cortex (DLPFC) compared with healthy
subjects (14). Considering the role of glutamate between subtypes
of bipolar disorder (i.e., type I vs. II), Atagun et al. found
neurochemical differences in superior temporal cortices (15),
i.e., BP-I had significantly lower Glu and glutamate+glutamine
(Glx) levels in comparison to BP-II. However, this finding
may be due to bipolar disorder type I consistently shown
to be taking more anti-psychotic medication (16). Therefore,
glutamate concentrations may provide information about
neuronal function during a particular mood episode, but also
reveal underpinnings that are common/distinct across types.
Indeed, the contribution to altered glutamate release/reuptake
activation may be related to cytokine effects within the
brain, leading to excitotoxicity and loss of glial elements,
consistent with altered effects on cognition and behavior.
Preliminary evidence shows that elevated inflammatory markers
are associated with elevated glutamatergic neurotransmission
(3), which subsequently correlated with poor processing speed.
In work investigating how inflammatory markers may impact
on the glutamatergic system, it has been shown that patients
exposed to the inflammatory cytokine interferon (IFN)-alpha
exhibited increased glutamate in left basal ganglia and dorsal
anterior cingulate cortex (dACC) in a group of patients with
hepatitis C and comorbid depression (17). In turn, high Glx, and
Glx/creatine levels have been also been shown to correlate with
cognitive impairment in various patient groups (18). A similar
process may occur in bipolar disorder, since recent evidence
shows elevated glutamate (10) and increased inflammatory
markers have also been reported in this patient group (19), albeit
in different patients. Increasing evidence is showing increased
CRP, IL_6, and TNFa levels in euthymic bipolar patients in
comparison to controls (20–22). Furthermore, elevated serum
levels of IL-1RA in BP subjects, even during euthymic states,
was found to be associated with worse cognitive function (23).
Thus, there are some intriguing suggestions that there may
be an interaction between inflammation, cognitive impairments
and increased brain glutamate levels in BP that require further
investigation (24).
The purpose of this study was three-fold. Firstly, we aimed
to measure ACC glutamatergic concentrations at rest (i.e., static
1H-MRS) in bipolar disorder type II (BP-II) compared with
healthy controls. Second, we aimed to examine any correlations
with neuropsychological performance on cognitive tests, and
peripheral inflammatory markers (CRP, IL_6, and TNF-a) to
investigate cytokine involvement on the glutamatergic system
and related effects on cognition and behavior. Lastly, we aimed
to assess if the presence of neuropsychological impairment
may in turn have subsequent effects on psychological treatment
outcomes. We hypothesized that higher levels in Glu, would be
associated with poorer cognitive performance in the BP-II group
compared with healthy controls and this would be related to the
inflammatory cytokines TNFa, CRP, and/or IL_6.
METHODS
Study Subjects
Fifteen patients with BP-II and thirteen healthy controls
aged 22–57 years were recruited into the study. The BP-
II group were recruited from the Predictors of Outcome
Following Psychological Therapy (PROMPT) study which aims
to investigate predictors of response to psychological therapy (2).
The PROMPT project is a large observational, naturalistic study
which investigates predictors of outcome following a range of
different psychological therapies, including cognitive behavioral
therapy (CBT), guided self-help and counseling, at Southwark
Talking Therapies, South London [for more information about
the PROMPT study, see (2)]. Healthy controls were recruited
through online advertisements. Bipolar patients were assessed
for euthymia prior to testing, using short behavioral assessments
to assess hypomania and depressive symptoms. However, three
people were depressed at the time of their assessment. Exclusion
criteria included any serious medical illness, or infection, and
substance abuse/dependence within the past 6 weeks (determined
by structured clinical interview for DSM-IV). No patients had
taken any medications known to affect the immune system
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within the past 6 months. 5/15 participants were taking anti-
depressant medications including citalopram and fluoxetine due
to the difficulty in recruiting patients who were medication
free. 10/15 patients were medication free. All participants signed
informed consent and the study was approved a priori by the
London—Harrow Research Ethics Committee, Ref 12/SC/0528.
Study Procedures
Study procedures occurred in the same order over either
1 or 2 days. 1H-MRS scans were conducted on Day 2, if
applicable, between 8 a.m. and 4 p.m. Blood sampling, behavioral
assessments and neurocognitive testing were conducted on the
same day as the brain scan, and neuropsychiatric assessments
were carried out on Day 1 if the session was split into two.
Psychological treatments for the BP-II group were delivered by
a qualified psychologist or psychological well-being practitioner
and all BP-II participants in this present study completed an
average of six therapy sessions. Therapy outcome data was
extracted from online patient records, as and when patients
completed therapy. Depressive symptom severity, using the
PHQ-9, is measured after each therapy session and at baseline.
Outcome for the present study is defined as the final PHQ-9 score
of the last therapy session received by each patient.
Behavioral Assessments
Depression severity was measured using the Montgomery–
Åsberg Depression Rating Scale (MADRS) (25). Hypomanic
symptoms were assessed using the Young Mania Rating Scale
(YMRS) (26). Therapy outcome scores for the 15 BP-II patients,
in the form of the Patient Health Qusetionnaire-9 (PHQ-9), were
obtained from the outcome phase of the PROMPT study in order
to assess baseline predictors of therapy outcome in the present
subsample of patients.
Neurocognitive Assessment
Executive function was assessed using the Trail Making Test B
and Intra Dimensional Extra Dimensional Shift of the Cambridge
Neuropsychological Test Automated Battery. The Rey Auditory
Verbal Learning Test (RAVLT) was used to measure verbal
learning and memory, and the Digit Symbol Substitution
Test of Wechsler Adult Intelligence Scale was used to assess
psychomotor processing speed. The Weschler Test of Adult
Reading was used to measure pre-morbid IQ.
Scanning Protocol
Scanning was performed on a GE 3-Tesla System (GE, 12-
channel head coil). For image guidance and prescription of
voxels of interest, axial T1 images were obtained using three-
dimensional magnetization-prepared rapid gradient-echo with
settings of time to repetition (TR) = 2,000 (ms), time to echo
(TE) = 30ms, time following inversion pulse (TI) = 1,100ms,
flip angle = 8◦ and voxel size 1 × 1 × 1 mm3. 1H-MRS was
acquired using the standard PRESS sequence with the following
parameters: TR = 2,000ms, TE = 30ms. See Figure 1 for our
voxel of interest.
1H-MRS Analysis
1H-MRS analysis was accomplished using LCModel. The water-
suppressed time-domain data were analyzed between 0.2 and
4.0 ppm. using the basis set provided by the vendor. T1-
weighted images were segmented into gray matter, white matter
and cerebrospinal fluid (CSF) compartments using Structural
Brain Mapping (SPM) software on the whole brain T1 images.
A volume of interest was generated on the T1 images, which
matched the location and size of 1H-MRS voxel. Volumes of
gray matter, white matter and CSF segments in this volume
of interest were then calculated. Since the Glu metabolite
measures were derived with water-scaling, a further correction
was applied to correct the estimated water concentration of the
voxel for partial volume CSF contamination. We used the same
default CSF, gray matter and white matter water concentrations
employed by LCModel (55,556, 43,300, and 35,880 mol/m3
respectively). For practical purposes, these correction factors
were combined into a single equation Mcorr =M∗(43,300∗gm +
35,880∗wm + 55,556∗CSF)/[35,880∗(1 – CSF)], which simplifies
to M∗(1.207∗gm + wm + 1.548 CSF)/(1 – CSF) where M=
uncorrected metabolite, wm, white matter fraction; gm, gray
matter fraction; and CSF, cerebrospinal fluid faction from the
spectroscopy voxel.
Immune Assessments
Blood was obtained in two EDTA tubes and were then
immediately stored at −80 ◦C until batched assay.
Concentrations of tumor necrosis factor (TNFa), interleukin 6
(IL_6), and C-reactive Protein (CRP) were assessed in duplicate
using multiplex bead-based assays. Blood samples were originally
collected from all individuals, however, at analysis stage, some
samples could not be found on the sample management system,
therefore we were left with 13 BP-II and 10 HC.
Statistical Analysis
Pearson product-moment correlation coefficient was performed
to assess the relationship between absolute Glu concentrations
in the dorsal Anterior Cingulate Cortex (dACC) and cognitive
tests (executive function, verbal learning and psychomotor
speed). Secondary analyses examined the relationship between
inflammatory markers and absolute Glu concentrations in the
dACC. Independent samples T-tests were used to examine the
differences in Glu, cognitive tests, and cytokines i.e., TNF-a, IL_6,
and CRP levels between groups, as well as age, sex, hypomanic
symptoms measured by YMRS and depression severity as
measured by the MADRS. All results were assessed for multiple
comparisons, using False Discovery Rate (FDR) analysis, in SPSS.
RESULTS
BP-II participants had significantly higher scores on YMRS and
MADRS compared to controls (see Table 1). There was no
significant difference between groups on WTAR. There was a
trend for a significant difference between healthy controls and
BP-II on the DST and no other significant differences between
groups on other cognitive tests, however BP-II tended to perform
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FIGURE 1 | Region of Interest (ROI). ACC Voxel measures 20 (AP) × 20 (RL) × 20 (SI) mm3 in size and the voxel was prescribed from the midline sagittal localizer,
with the center of the voxel placed 16mm above the genu of corpus callosum perpendicular to the AC–PC line.
TABLE 1 | Mean and standard deviations of clinical and cognitive characteristics.
Healthy control
n = 13
Bipolar disorder
n= 15
M SD M SD t-value p-value
YMRS 0.69 1.03 4.36 3.89 3.395 0.004
MADRS 0 0 9.43 12.42 −2.840 0.014
DST 90 18.3 73 24.5 2.005 0.052
RAVLT 56 9.7 51 39.6 1.706 0.996
TMT-B 60.78 36.9 60.85 28.1 −0.005 0.107
WTAR 45.67 4.812 46.21 3.017 −0.341 0.152
less well. See Table 1. The BP-II group had significant psychiatric
co- morbidity compared to healthy controls, see Table 2.
Bipolar Disorder Type II (BP-II) vs. Healthy
Control
Glutamate (Corrected for CSF/Gray/White Matter)
There was no significant difference in anterior cingulate Glu
levels between BP-II (M= 15.92, SD= 1.67) and HC (M= 15.17,
SD= 1.50), t(−1.420, p= 0.227).
Inflammatory Markers
There were no significant differences in TNFa, IL_6, or CRP
levels between BP-II and healthy controls. See Table 3.
TNFa, IL_6, CRP vs. Glu in BP-II
There were no significant relationships between TNFa (r= 0.103,
p = 0.512), IL_6 (r = 0.211, p = 0.345), and CRP (r = 0.356,
p= 0.435) with Glu levels in the BP-II group.
TABLE 2 | Co-morbidities in the patient sample (BP-II).
Diagnosis N %
Suicide risk 8 50%
Panic disorder 6 43%
Agoraphobia 5 31%
OCD 1 6%
PTSD 3 12%
Alcohol dependence 1 6%
Alcohol abuse 1 6%
Psychosis 3 12%
Generalized Anxiety Disorder (GAD) 4 19%
Glu vs. Cognitive Data in BP-II
There were no significant relationships between scores on the
DST and Glu levels in patients (r = −0.436, p = 0.120) and
no relationship between scores on TMT-B and Glu levels in the
BP-II group (r = 0.194, p = 0.524). There were no significant
correlations between Glu and RAVLT or WTAR.
Digit Symbol Task vs. Outcome
Scores on the DST were significantly associated with therapy
treatment outcome following psychological therapy (r =−0.582,
p= 0.037), i.e., worse performance on the DST is associated with
higher depressive severity following treatment.
DISCUSSION
We found higher levels of CRP, IL_6 and TNFa and elevated
levels of dACC Glu in bipolar patients in comparison to controls,
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TABLE 3 | BP-II vs. healthy control—TNFa, IL_6, CRP.
N Mean SD p-value t-value
TNFa
Healthy control 10 1.7730 0.44242 0.221 −1.322
Bipolar disorder 13 2.0215 0.45284
IL_6
Healthy control 10 0.53 0.371 0.792 −0.267
Bipolar disorder 13 0.58 0.479
CRP
Healthy control 10 3.02 2.79 0.400 −0.871
Bipolar disorder 13 5.23 4.81
however the differences were not significant. We found that BP-
II subjects tended to perform worse in cognitive tests however
the difference were not significant between groups. There was
a trend for significance on the DST measure of processing
speed (p = 0.052) between groups. In turn, we found that
reduced processing speed was associated with a poor outcome to
psychological treatment.
Our findings contribute to our understanding of neural
correlates of Bipolar Disorders that are characterized as having
impaired cognitive function (i.e., difficulties in attention and
concentration are together, a hallmark of both major depression
and hypomania).
LIMITATIONS
The study was designed as a pilot, and as such has a small sample
size. As a result, it is possible that some of the negative findings
may have been due to a lack of power. Although all patients were
assessed as euthymic at screening, three patients were depressed
at the time of their scan. Strict euthymic samples should be
investigated in further samples. The authors note that although
no significant differences were found between groups, the lead
author of this study extracted participants who were depressed
on the day of the scan and the mean differences in Glu levels
between patients and controls were larger, although again, not
significantly so. The patients in this study were not excluded
based on the use of anti-depressants, given the challenge of
recruiting patients with BP-II without medication (12). Although
10/15 patients were not taking anti-depressants, the results could
have been influenced by those who were on medication.
CONCLUSIONS
Two evolving theories regarding the development of mood
disorders involve excessive activation of inflammatory pathways
and alterations in glutamate metabolism. In the present study,
we did not find a significant comparison for the involvement
of inflammation or in glutamate levels between groups. The
reason for this may be in part due to the small sample size,
especially as our findings show elevated levels of both cytokines
and Glu, which fits with our hypothesis, although not significant.
It could also mean that peripheral inflammation is not related
to brain Glu in the dACC. Nevertheless, cognitive impairment,
and particularly in the area of processing speed, appears to
be an important and novel treatment target for improving
neuropsychological function in BP-II groups. Improving such
factors may lead to better outcomes to psychological therapy and
related treatments.
Future work in our group will aim to further characterize
the relationship between inflammation, mood and glutamatergic
neurotransmission.
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